Separation anxiety in dogs: clomipramine plus behaviour therapy vs behaviour therapy alone — POSSIBLE

In dogs with separation anxiety, does clomipramine plus behaviour therapy vs behaviour therapy alone reduce anxiety signs?

Shelf #300 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE: Adding standard-dose clomipramine (1 to <2 mg/kg PO every 12 hours) to behavioural therapy helped dogs with separation anxiety faster than behavioural therapy with placebo, in a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial of 95 dogs (King 2000): dogs on the standard dose were rated improved at least three times faster — a relative rate, as the record gives no absolute improvement rates — for the signs destruction, defecation and urination, and at most time points more standard-dose dogs were rated improved for those signs and on an owner's global assessment of overall behaviour (p<0.05 at certain time points). Two qualifications are on the face of the record: there were no statistically significant differences at any time point for vocalization, and low-dose clomipramine (0.5 to <1 mg/kg every 12 hours) produced no statistically significant effect compared with placebo. POSSIBLE rather than higher because the record reports no absolute rates, significance held only at certain time points, and the record does not name who rated the individual signs (the global assessment was the owner's). Drafted Nov 10, 2026 (VetMed build, topic #300); all figures from abstracts fetched and verified at drafting.

King 2000: standard-dose clomipramine rated improved at least three times faster than placebo on destruction, defecation and urination (95 dogs)

Prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial (record's own title wording)

Who: Dogs: 95 dogs diagnosed with separation anxiety — each had to exhibit at least one of destruction, defecation, urination and/or vocalization in the owner's absence, as well as behaviour suggestive of "hyper-attachment" to the owner — randomized to standard-dose clomipramine (1 to <2 mg/kg, PO, q. 12 h), low-dose clomipramine (0.5 to <1 mg/kg, PO, q. 12 h), or placebo (PO, q. 12 h) for 2-3 months; all dogs received behavioural therapy, and dogs were examined at days 0, 28, 56 and 84. Improvement at each visit was evaluated against day 0; the record does not name who rated the individual signs, and the one scorer it does name is the owner, for the global assessment of the dog's overall behaviour. The trial design is stated as double-blind in the title and abstract, so raters and owners were blinded per the record's own wording.

Result: Compared to placebo, dogs receiving standard-dose clomipramine were rated improved at least three times faster for the signs destruction, defecation and urination — a relative rate of improvement; the record gives no absolute proportions improved, and none are carded here. At most time points, more dogs in the standard-dose group were rated improved for destruction, defecation and urination, and in an owner's global assessment of the dog's overall behaviour (p<0.05 at certain time points). However, there were no statistically significant differences at any time point between the standard dose and placebo groups in the sign vocalization, and the low-dose clomipramine group produced no statistically significant effect when compared with placebo. Mild and transient vomiting was noted as a side effect of clomipramine in a small number of dogs.

Watch out: The headline 'three times faster' is a relative rate with no absolutes beside it in the record — do not read it as three times as many dogs improved. Significance is reported only as p<0.05 at certain (unnamed) time points across four signs and three visits, a pattern open to multiplicity, and one of the four target signs (vocalization) was null throughout. This record carries no MeSH terms at all (see source line), and its journal is Applied Animal Behaviour Science — not the journal named in the draft topic list.

King JN, Simpson BS, Overall KL, Appleby D, Pageat P, Ross C, Chaurand JP, Heath S, Beata C, Weiss AB, Muller G, Paris T, Bataille BG, Parker J, Petit S, Wren J. Treatment of separation anxiety in dogs with clomipramine: results from a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial. Appl Anim Behav Sci. 2000;67(4):255-275. PMID: 10760607. Registry ID: none in the record. MeSH: none in the record

Synthesis: standard-dose clomipramine speeds improvement on three of four signs — dose and sign both matter

Synthesis

Who: Synthesis of the card above: King 2000 (prospective randomized double-blind placebo-controlled parallel-group multicenter trial, 95 dogs, all receiving behavioural therapy).

Result: The one blinded placebo-controlled trial supports standard-dose (1 to <2 mg/kg twice daily), not low-dose, clomipramine as an adjunct to behavioural therapy: faster rated improvement for destruction, defecation and urination and a better owner global assessment at some time points, with no effect on vocalization and only mild transient vomiting in a small number of dogs. Because the record withholds absolute rates and per-time-point detail, the size of the benefit in an individual dog cannot be quantified from this shelf — POSSIBLE is the calibrated stamp.

Watch out: Every dog in the trial received behavioural therapy as well as drug or placebo, so the record supports clomipramine as an add-on, never as a substitute for the behaviour plan; and the benefit is sign-specific — owners whose dog's main problem is vocalization should not expect the trialled benefit.

Synthesis of King JN et al. PMID: 10760607. Registry ID as on the individual card.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.